[go: up one dir, main page]

HK1244804A1 - 4h-吡咯並[3,2-c]吡啶-4-酮衍生物 - Google Patents

4h-吡咯並[3,2-c]吡啶-4-酮衍生物

Info

Publication number
HK1244804A1
HK1244804A1 HK18104306.1A HK18104306A HK1244804A1 HK 1244804 A1 HK1244804 A1 HK 1244804A1 HK 18104306 A HK18104306 A HK 18104306A HK 1244804 A1 HK1244804 A1 HK 1244804A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
pyridin
derivatives
Prior art date
Application number
HK18104306.1A
Other languages
English (en)
Inventor
Keith Graham
Ulrich Klar
Hans Briem
Volker Schulze
Gerhard Siemeister
Philip Lienau
René Tempel
Jozsef Bálint
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1244804A1 publication Critical patent/HK1244804A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18104306.1A 2015-01-28 2018-03-29 4h-吡咯並[3,2-c]吡啶-4-酮衍生物 HK1244804A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152944 2015-01-28
EP15200407 2015-12-16
PCT/EP2016/051432 WO2016120196A1 (en) 2015-01-28 2016-01-25 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Publications (1)

Publication Number Publication Date
HK1244804A1 true HK1244804A1 (zh) 2018-08-17

Family

ID=55236350

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104306.1A HK1244804A1 (zh) 2015-01-28 2018-03-29 4h-吡咯並[3,2-c]吡啶-4-酮衍生物

Country Status (31)

Country Link
US (1) US10428063B2 (zh)
EP (1) EP3250567B1 (zh)
JP (1) JP6704398B2 (zh)
KR (1) KR102544847B1 (zh)
CN (1) CN107406417B (zh)
AU (1) AU2016212230B2 (zh)
BR (1) BR112017016193B1 (zh)
CA (1) CA2974853C (zh)
CL (1) CL2017001930A1 (zh)
CO (1) CO2017007663A2 (zh)
CR (1) CR20170345A (zh)
CU (1) CU20170094A7 (zh)
DO (1) DOP2017000176A (zh)
EA (1) EA032530B1 (zh)
EC (1) ECSP17048527A (zh)
HK (1) HK1244804A1 (zh)
IL (1) IL253284B (zh)
JO (1) JO3706B1 (zh)
MX (1) MX380239B (zh)
MY (1) MY182181A (zh)
NI (1) NI201700096A (zh)
PE (1) PE20171240A1 (zh)
PH (1) PH12017501340A1 (zh)
SG (1) SG11201705908VA (zh)
SV (1) SV2017005487A (zh)
TN (1) TN2017000329A1 (zh)
TW (1) TWI699359B (zh)
UA (1) UA122221C2 (zh)
UY (1) UY36544A (zh)
WO (1) WO2016120196A1 (zh)
ZA (1) ZA201705802B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952307A1 (en) 2014-06-17 2015-12-23 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2016202755A1 (en) 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017021348A1 (en) * 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
MD3390395T2 (ro) 2015-12-16 2021-02-28 Loxo Oncology Inc Compuși utili ca inhibitori ai kinazei
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102440006B1 (ko) 2017-08-23 2022-09-05 현대모비스 주식회사 차량용 브레이크의 캘리퍼 장치
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
US12240844B2 (en) 2019-01-18 2025-03-04 Voronoi, Inc. Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
US12227501B2 (en) 2019-02-07 2025-02-18 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors
JP7641913B2 (ja) 2019-04-24 2025-03-07 バイエル・アクチエンゲゼルシヤフト 4h-ピロロ[3,2-c]ピリジン-4-オン化合物
US20240307362A1 (en) 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
US20220378762A1 (en) * 2019-04-24 2022-12-01 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4509122A2 (en) 2020-07-29 2025-02-19 Bayer Aktiengesellschaft Substituted heterocyclic compounds and therapeutic uses thereof
EP4188928B1 (en) 2020-07-29 2024-07-24 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
EP4188551B1 (en) 2020-07-29 2024-12-18 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
EP4480480A3 (en) 2020-07-29 2025-02-26 Bayer AG Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
WO2022033416A1 (zh) * 2020-08-10 2022-02-17 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
AU2021347288A1 (en) 2020-09-23 2023-05-04 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072645A2 (en) * 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
EP4469457A1 (en) * 2022-01-27 2024-12-04 The Broad Institute Inc. Substituted heterocyclic csnk1 inhibitors
CN119698415A (zh) 2022-03-24 2025-03-25 蝎子疗法股份有限公司 合成egfr抑制剂的方法
WO2024182715A1 (en) * 2023-03-02 2024-09-06 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
ES2389673T3 (es) 2007-09-28 2012-10-30 Nerviano Medical Sciences S.R.L. Derivados de pirrolopirimidina sustituidos, procedimiento para su preparación y su uso como inhibidores de quinasas
MX2010007525A (es) * 2008-01-22 2010-08-18 Vernalis R&D Ltd Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control.
EP2443117B1 (en) 2009-06-15 2016-03-23 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EP2788350B1 (en) * 2011-10-07 2017-12-06 Nerviano Medical Sciences S.r.l. 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
EP2771321A4 (en) 2011-10-28 2015-04-08 Chong Kun Dang Pharm Corp HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
CA2859779A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CA2872933A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment cancer
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
CN104870446B (zh) 2012-11-07 2019-08-13 内尔维阿诺医学科学有限公司 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
JP2016514719A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ヘテロアリール置換インダゾール
US9745285B2 (en) 2013-06-21 2017-08-29 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2014202588A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EP3010902A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2014202590A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
CA2952307A1 (en) * 2014-06-17 2015-12-23 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2016202755A1 (en) 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017021348A1 (en) 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
US20200216439A1 (en) 2015-12-16 2020-07-09 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones

Also Published As

Publication number Publication date
US10428063B2 (en) 2019-10-01
TN2017000329A1 (en) 2019-01-16
CN107406417B (zh) 2020-06-09
CA2974853A1 (en) 2016-08-04
TWI699359B (zh) 2020-07-21
IL253284A0 (en) 2017-09-28
JO3706B1 (ar) 2021-01-31
JP2018503648A (ja) 2018-02-08
EP3250567B1 (en) 2019-10-30
EP3250567A1 (en) 2017-12-06
ZA201705802B (en) 2019-07-31
MY182181A (en) 2021-01-18
CR20170345A (es) 2017-09-29
MX2017009831A (es) 2017-11-02
PE20171240A1 (es) 2017-08-24
CU20170094A7 (es) 2017-12-08
KR102544847B1 (ko) 2023-06-16
JP6704398B2 (ja) 2020-06-03
PH12017501340A1 (en) 2017-12-18
CL2017001930A1 (es) 2018-03-09
MX380239B (es) 2025-03-12
TW201639828A (zh) 2016-11-16
SG11201705908VA (en) 2017-08-30
EA201791692A1 (ru) 2018-01-31
WO2016120196A1 (en) 2016-08-04
SV2017005487A (es) 2019-01-17
UY36544A (es) 2016-08-31
CN107406417A (zh) 2017-11-28
KR20170106452A (ko) 2017-09-20
NI201700096A (es) 2017-10-24
UA122221C2 (uk) 2020-10-12
ECSP17048527A (es) 2017-10-31
DOP2017000176A (es) 2017-08-31
EA032530B1 (ru) 2019-06-28
BR112017016193B1 (pt) 2023-02-23
AU2016212230A1 (en) 2017-07-20
US20180016272A1 (en) 2018-01-18
CA2974853C (en) 2023-02-21
AU2016212230B2 (en) 2019-09-19
IL253284B (en) 2020-08-31
BR112017016193A2 (pt) 2018-04-17
CO2017007663A2 (es) 2017-10-10

Similar Documents

Publication Publication Date Title
HK1244804A1 (zh) 4h-吡咯並[3,2-c]吡啶-4-酮衍生物
HK1259623A1 (zh) 作爲irak4調節劑的吡唑並[1,5a]嘧啶衍生物
IL252065A0 (en) Thiano[2,3-c]pyrrol-4-ion derivatives as erk inhibitors
IL250823A0 (en) A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
EP3154970A4 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
ZA201808257B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
HK1256614A1 (zh) 經取代的1,2-二氫-3h-吡咯並[1,2-c]咪唑-3-酮抗菌化合物
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
EP3380475A4 (en) OCTAHYDROPYRROLO [3,4-C
PT3129374T (pt) (5,6-dihidro)pirimido[4,5-e] indolizinas
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (zh) 2,3,4,5-四氫吡啶-6-胺衍生物
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
GB201300892D0 (en) Novel isothiazolo[4,3-b]pyridines
TH1601002954A (th) ออกตะไฮโดร-ไซโคลบิวตะ[1,2-c;3,4-c']ไดไพร์โรล-2-อิล ใหม่